Centre for Rheumatology and Bloomsbury Rheumatology Unit
Rheumatology Bloomsbury is part of the Division of Medicine
Published: Apr 11, 2014 11:08:00 AM
Published: Apr 3, 2014 10:08:20 AM
Published: Mar 24, 2014 9:39:50 AM
The centre undertakes clinical and basic research to increase our understanding of the cause of musculoskeletal diseases and improve their management.
As well as seeing around 3,000 new patients and 15,000 follow ups annually, the centre undertakes an enormous amount of clinical and basic research aimed at increasing our understanding of the cause of musculoskeletal diseases and improving their management.
The research component of the centre is based in laboratories part funded by the Arthritis Research UK (ARUK)
in the Rayne Building (University Street).
Our laboratory based research focuses on the
structure, function, origin and pathogenic consequences of
autoantibodies; B and T cell regulation, lipid rafts and the molecular
effects of statins.
We hold an Oliver Bird PhD programme grant from the Nuffield Foundation, two program grants from the ARUK, several research fellowships (ARUK and Welcome Trust funded) and many projects grants. Its success can be judged by our total grant income being in excess of £9,000,000 in the past four years, and outside of its institutes, is the largest single centre beneficiary of ARUK funds in the UK (all achieved through competitive awards).
group focuses its interests on B cell depletion (an idea which they
introduced (with the now retired Professor Jo Edwards) approximately 10 years ago for the treatment of rheumatoid
arthritis), exploring more precisely how the technique works and trying
to explain the marked variation in response between different patients.
She has a strong clinical collaboration with Dr Maria Leandro.
Professor Ehrenstein leads a research group investigating the
immunoregulation of autoimmune rheumatic disease and is particularly
interested in how novel therapies modulate the autoimmune response in
the context of rheumatoid arthritis (RA) and systemic lupus
The use of novel biologic therapies represents an
important tool to understand the aberrant immune responses found in
patients with autoimmunity.
In this context, his research group has
been studying the phenotype, functional and molecular characteristics of
regulatory T cells in patients with RA and SLE before and after
He has also been focusing on the pathogenic and regulatory properties of B cells in patients with SLE as well as investigating the tolerogenic nature of secreted IgM.
Professor Grahame is one of the world's leaders in hypermobility syndrome focusing on its range of clinical diversity, aetio pathogenesis and improving the management of the condition.
has a long standing interest in the structure, function,
origin and pathogenecity of anti-DNA antibodies and antiphospholipid
Professor Isenberg has a great interest in the
establishment of "tools" used to assess patients with Systemic Lupus
Erythematosus, Myositis, and Sjogren's Syndrome.
He undertakes long
term observational studies of these conditions and has run many trials
of biological therapies for patients who have them.
In 2010 he was the first North-American to be awarded the Hess Prize for outstanding contribution to the study of systemic lupus erythematosus.
Jury's interests focus on abnormalities in signaling within both T and
B lymphocytes, in particularly within the area of the cell known as the
She, too, focuses on abnormalities in the context of Systemic Lupus Erythematosus.
Professor Claudia Mauri's main interest is the identification,
functional analysis and the genetical characterization of regulatory B
cells. Her complementary interest includes the understanding of the
cause of the loss of regulation of immune responses (regulatory B and T
cells), which may be the cause of rheumatoid arthritis (RA) and systemic
lupus erythematosus (SLE).
She is the postgraduate tutor for
inflammation in the Division of Medicine and the course organiser for
Immunology in Health and Disease.
Professor Anisur Rahman / Dr Ian Giles / Dr John Ioannou
group focuses on the structure, function, origin and pathogenic
consequences of the antiphospholipid antibodies.
These antibodies are
linked to a predisposition to arterial and venous clotting and an
increase in the risk of pregnancy losses - the clinical condition known
as the antiphospholipid antibody syndrome.
They are working on understanding at a cellular level how these antibodies cause clinical effects and on the development of a novel therapeutic agent.